3 Forgotten Small-Caps Under $5B Nobody Is Watching Right Now

Everyone's got an opinion on $AMZN right now. Nobody has an opinion on the three names below, which is exactly the point. While sentiment data shows retail traders piling into the same handful of AI darlings and war-trade energy plays, a few genuinely overlooked small-caps are sitting quietly with tightening setups and identifiable catalysts. Let's fix that.

$PCVX (Vaxcyte) is a clinical-stage vaccine company out of San Carlos, California, with a market cap sitting comfortably under $5 billion. Most people couldn't name their lead program, PC31, a pneumococcal vaccine candidate targeting a broader antigen coverage than anything Pfizer's Prevnar franchise currently offers. Why is it under the radar? Because it hasn't generated a single dollar of revenue yet, which scares off the screener crowd. But the Phase 3 STRIDE-7 readout expected in the next two quarters is the kind of binary catalyst that turns a sleepy biotech into a front-page name overnight. The bull case is simple: broader serotype coverage than the market leader in a multi-billion-dollar market. The bear case is equally simple: clinical trials fail all the time. Position sizing matters here.

$ACVA (ACV Auctions) flies even further under the radar. This is a NASDAQ-listed digital wholesale auto auction platform connecting independent dealers across the US, with a market cap under $3 billion. While everyone argues about whether used car prices are going up or down, ACV is quietly building a marketplace that benefits from volume regardless of direction. The company reported accelerating revenue growth in its last print, and the bull thesis is that dealer fragmentation in the used car market is still enormous, meaning the runway for platform penetration is long. The bear case: the business burns cash and competes indirectly with massive incumbents like Manheim. Still, unusual volume chatter around this name earlier in the week suggests someone is paying attention.

$IIPR (Innovative Industrial Properties) is the one that surprises people. It's a REIT, specifically a cannabis-focused REIT, trading well below its 2021 highs and sitting under a $2 billion market cap. What makes it interesting right now is the spread between its dividend yield and where long-end rates appear to be heading, per the Bloomberg podcast discussion of 10-year yields potentially approaching 5.5%. That's a headwind, full stop. But IIPR leases mission-critical cultivation facilities on long-term triple-net leases, meaning tenants cover taxes, insurance, and maintenance. If cannabis rescheduling gains momentum in any form, this is the picks-and-shovels play that already has a functional operating history. It's a speculative hold until the rate picture clears.

The common thread across all three: low institutional coverage, identifiable upcoming catalysts, and names that don't show up in anyone's AI ETF. Sometimes the best trades are the ones the algorithm forgot to find.